Mauer Murielle E L, Taphoorn Martin J B, Bottomley Andrew, Coens Corneel, Efficace Fabio, Sanson Marc, Brandes Alba A, van der Rijt Carin C D, Bernsen Hans J J A, Frénay Marc, Tijssen Cees C, Lacombe Denis, van den Bent Martin J
European Organisation for Research and Treatment of Cancer Data Center, Quality of Life Unit, Ave Mounier 83/11, Brussels, Belgium 1200.
J Clin Oncol. 2007 Dec 20;25(36):5731-7. doi: 10.1200/JCO.2007.11.1476.
This is one of a few studies that have explored the value of baseline symptoms and health-related quality of life (HRQOL) in predicting survival in patients with brain cancer.
Baseline HRQOL scores (from the European Organisation for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire C30 and the EORTC Brain Cancer Module) were examined in 247 patients with anaplastic oligodendrogliomas to determine the relationship with overall survival by using Cox proportional hazards regression models. Refined techniques as the bootstrap resampling procedure and the computation of C indexes and R2 coefficients were used to explore the stability of the models as well as better assess the potential benefit of using HRQOL to predict survival in clinical practice and research.
Classical analysis controlled for major clinical prognostic factors selected emotional functioning (P = .0016), communication deficit (P = .0261), future uncertainty (P = .0481), and weakness of legs (P = .0001) as statistically significant prognostic factors of survival. However, several issues question the validity of these findings and no single model was found to be preferable over all others. C indexes, which estimate the probability of a model to correctly predict which patient among a randomly chosen pair of patients will survive longer, and R2 coefficients, which measure the proportion of variability explained by the model, did not exhibit major improvement when adding selected or all HRQOL scores to clinical factors.
While classical techniques lead to positive results, more refined analyses suggest that baseline HRQOL scores add relatively little to clinical factors to predict survival. These results may have implications for future use of HRQOL as a prognostic factor for patients with cancer.
本研究是少数几项探讨基线症状和健康相关生活质量(HRQOL)对脑癌患者生存预测价值的研究之一。
对247例间变性少突胶质细胞瘤患者的基线HRQOL评分(来自欧洲癌症研究与治疗组织[EORTC]生活质量问卷C30和EORTC脑癌模块)进行检查,通过Cox比例风险回归模型确定其与总生存的关系。采用如自助重采样程序以及C指数和R2系数计算等精细技术来探索模型的稳定性,并更好地评估在临床实践和研究中使用HRQOL预测生存的潜在益处。
对主要临床预后因素进行控制的经典分析选择了情绪功能(P = 0.0016)、沟通障碍(P = 0.0261)、未来不确定性(P = 0.0481)和腿部无力(P = 0.0001)作为生存的统计学显著预后因素。然而,一些问题对这些发现的有效性提出了质疑,未发现单一模型优于其他所有模型。当将选定的或所有HRQOL评分添加到临床因素中时,用于估计模型正确预测随机选择的一对患者中哪名患者生存期更长概率的C指数以及衡量模型解释变异比例的R2系数并未显示出显著改善。
虽然经典技术得出了阳性结果,但更精细的分析表明,基线HRQOL评分在预测生存方面对临床因素的补充相对较少。这些结果可能对未来将HRQOL用作癌症患者的预后因素具有启示意义。